Published in Clin Diagn Lab Immunol on March 01, 1995
Expression of the somatostatin gene in human astrocytoma cell lines. Clin Diagn Lab Immunol (1996) 0.75
Measles virus modulates human T-cell somatostatin receptors and their coupling to adenylyl cyclase. J Virol (1997) 0.75
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol (1992) 5.78
Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1 alpha. J Biol Chem (1989) 5.09
Sequence of the human somatostatin I gene. Science (1984) 3.48
The SCID-hu mouse as a model for HIV-1 infection. Nature (1993) 3.43
Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. J Exp Med (1993) 2.81
Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc Natl Acad Sci U S A (1993) 1.96
AIDS enteropathy. Clin Infect Dis (1992) 1.76
CD8+ cell anti-HIV activity: nonlytic suppression of virus replication. AIDS Res Hum Retroviruses (1992) 1.75
Induction of CD4 and susceptibility to HIV-1 infection in human CD8+ T lymphocytes by human herpesvirus 6. Nature (1991) 1.73
Regulation of HIV-1 gene expression. Annu Rev Immunol (1990) 1.66
CD8+CD4- lymphocyte lines can harbor the AIDS virus in vitro. J Immunol (1989) 1.60
Evidence for susceptibility of intrathymic T-cell precursors and their progeny carrying T-cell antigen receptor phenotypes TCR alpha beta + and TCR gamma delta + to human immunodeficiency virus infection: a mechanism for CD4+ (T4) lymphocyte depletion. Proc Natl Acad Sci U S A (1990) 1.43
Regional specialization of the mucosal immune system. Intraepithelial lymphocytes of the large intestine have a different phenotype and function than those of the small intestine. J Immunol (1993) 1.39
Loss of CD4 membrane expression and CD4 mRNA during acute human immunodeficiency virus replication. J Exp Med (1988) 1.31
Human immunodeficiency virus infection of enterocytes and mononuclear cells in human jejunal mucosa. Gastroenterology (1991) 1.23
Differential response to the cytopathic effects of human T-cell lymphotropic virus type III (HTLV-III) superinfection in T4+ (helper) and T8+ (suppressor) T-cell clones transformed by HTLV-I. Proc Natl Acad Sci U S A (1986) 1.16
A lectin-binding soluble factor released by CD8+CD57+ lymphocytes from AIDS patients inhibits T cell cytotoxicity. Eur J Immunol (1991) 1.16
Identification of human mononuclear leukocytes bearing receptors for somatostatin and glucagon. Diabetes (1981) 1.14
Detection of HIV in enterochromaffin cells in the rectal mucosa of an AIDS patient. Am J Gastroenterol (1989) 1.11
Detection of unintegrated human immunodeficiency virus type 1 DNA in persistently infected CD8+ cells. J Gen Virol (1993) 1.07
Infection of CD8+ T lymphocytes with HIV. Requirement for interaction with infected CD4+ cells and induction of infectious virus from chronically infected CD8+ cells. J Immunol (1991) 1.04
Purification of the main somatostatin-degrading proteases from rat and pig brains, their action on other neuropeptides, and their identification as endopeptidases 24.15 and 24.16. Eur J Biochem (1992) 1.00
Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem (1989) 0.97
Somatostatin receptors on human lymphocytes and leukaemia cells. Immunology (1990) 0.94
Granuloma T lymphocytes in murine schistosomiasis mansoni have somatostatin receptors and respond to somatostatin with decreased IFN-gamma secretion. J Immunol (1992) 0.93
Modulation of T lymphocyte function by neuropeptides. Evidence for their role as local immunoregulatory elements. J Immunol (1993) 0.92
Natural killer cell infection and inactivation in vitro by the human immunodeficiency virus. Hum Pathol (1988) 0.91
Lysis of CD4+ lymphocytes by non-HLA-restricted cytotoxic T lymphocytes from HIV-infected individuals. Clin Exp Immunol (1993) 0.89
Somatostatin reduces the release of colony-stimulating activity (CSA) from PHA-activated mouse spleen lymphocytes. Experientia (1978) 0.88
Direct in vitro infection of human intestine with HIV-1. AIDS (1992) 0.87
Effect of vasoactive intestinal peptide, somatostatin, and substance P on spontaneous IgE and IgG4 production in atopic patients. J Immunol (1993) 0.87
Evidence that somatostatin is localized and synthesized in lymphoid organs. Proc Natl Acad Sci U S A (1991) 0.87
Suppression of superoxide release from human monocytes by somatostatin-related peptides. Regul Pept (1992) 0.84
In vitro non-productive infection of purified natural killer cells by the BRU isolate of the human immunodeficiency virus type 1. J Gen Virol (1993) 0.84
Inhibition by somatostatin of the release of mediators from human basophils and rat leukemic basophils. J Immunol (1984) 0.83
Somatostatin and vasoactive intestinal peptide reduce interferon gamma production by human peripheral blood mononuclear cells. Immunobiology (1990) 0.82
Cytokines from vaccine-induced HIV-1 specific cytotoxic T lymphocytes: effects on viral replication. AIDS Res Hum Retroviruses (1993) 0.81
Peptides in the gastrointestinal tract in human immunodeficiency virus infection. The GI/HIV Study Group of the University of Calgary. Gastroenterology (1992) 0.81
In vitro studies of immunoregulation by substance P and somatostatin. Ann N Y Acad Sci (1987) 0.81
Differential replication of human immunodeficiency virus type 1 in CD8- and CD8+ subsets of natural killer cells: relationship to cytokine production pattern. J Virol (1993) 0.81
The effect of somatostatin on the production of human interferons by mononuclear cells. Proc Soc Exp Biol Med (1990) 0.80
Interleukin-3 modulation of mouse bone marrow derived mast cell receptors for somatostatin. J Neurosci Res (1987) 0.79
Vasoactive intestinal peptide 1-12: a ligand for the CD4 (T4)/human immunodeficiency virus receptor. J Neurosci Res (1987) 0.78
Efficacy of octreotide in the management of chronic diarrhoea in AIDS. AIDS (1991) 0.78
Elevated plasma levels of vasoactive intestinal peptide in AIDS patients with refractory idiopathic diarrhoea. Effects of treatment with octreotide. AIDS (1993) 0.78
Increase in double-positive CD4+CD8+ peripheral T-cell subsets in an HIV-infected patient. AIDS (1993) 0.77
Somatostatin production by a human medullary thyroid carcinoma cell line. Endocrinology (1986) 0.76
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 3.57
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. J Virol (1992) 3.46
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 3.00
Role of Pr160gag-pol in mediating the selective incorporation of tRNA(Lys) into human immunodeficiency virus type 1 particles. J Virol (1994) 2.94
In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine. J Virol (1992) 2.85
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1994) 2.81
Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother (1991) 2.40
Effects of alterations of primer-binding site sequences on human immunodeficiency virus type 1 replication. J Virol (1994) 2.37
Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J Biol Chem (1994) 2.28
Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1. Virology (1993) 1.94
Rapid, reproducible enzyme immunoassay for gentamicin. J Clin Microbiol (1980) 1.92
Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 1.86
The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol (2000) 1.84
High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J Virol (1990) 1.83
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS (1998) 1.81
Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J Infect Dis (1990) 1.73
Mutations in the kissing-loop hairpin of human immunodeficiency virus type 1 reduce viral infectivity as well as genomic RNA packaging and dimerization. J Virol (1997) 1.68
AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells. Virology (1990) 1.64
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev (1995) 1.63
Agar disk diffusion susceptibility characteristics of azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillin. Antimicrob Agents Chemother (1979) 1.60
Effects of mutations in Pr160gag-pol upon tRNA(Lys3) and Pr160gag-plo incorporation into HIV-1. J Mol Biol (1997) 1.58
Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. Proc Natl Acad Sci U S A (1995) 1.56
HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. Arch Biochem Biophys (1999) 1.55
Inhibition of gp160 and CD4 maturation in U937 cells after both defective and productive infections by human immunodeficiency virus type 1. J Virol (1991) 1.50
The role of Pr55(gag) in the annealing of tRNA3Lys to human immunodeficiency virus type 1 genomic RNA. J Virol (1999) 1.49
Incorporation of excess wild-type and mutant tRNA(3Lys) into human immunodeficiency virus type 1. J Virol (1994) 1.49
Human immunodeficiency virus type 1 reverse transcriptase and early events in reverse transcription. Adv Virus Res (1996) 1.48
The role of nucleocapsid and U5 stem/A-rich loop sequences in tRNA(3Lys) genomic placement and initiation of reverse transcription in human immunodeficiency virus type 1. J Virol (1998) 1.47
Effects of modifying the tRNA(3Lys) anticodon on the initiation of human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 1.42
Initiation of (-) strand DNA synthesis from tRNA(3Lys) on lentiviral RNAs: implications of specific HIV-1 RNA-tRNA(3Lys) interactions inhibiting primer utilization by retroviral reverse transcriptases. Proc Natl Acad Sci U S A (1996) 1.39
The importance of the A-rich loop in human immunodeficiency virus type 1 reverse transcription and infectivity. J Virol (1997) 1.37
K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother (1995) 1.36
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses (1997) 1.36
Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis (2012) 1.36
The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev (1995) 1.34
Variable tRNA content in HIV-1IIIB. Biochem Biophys Res Commun (1992) 1.34
Detection of human immunodeficiency virus type 1 (HIV-1) in genital ulcer exudate of HIV-1-infected men by culture and gene amplification. J Infect Dis (1990) 1.33
DNA found in human immunodeficiency virus type 1 particles may not be required for infectivity. J Gen Virol (1994) 1.32
Sequences within Pr160gag-pol affecting the selective packaging of primer tRNA(Lys3) into HIV-1. J Mol Biol (2000) 1.32
Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC. J Gen Virol (1995) 1.31
Role of the mononuclear phagocyte system in the development of acquired immunodeficiency syndrome (AIDS). J Leukoc Biol (1988) 1.29
Temporal coordination between initiation of HIV (+)-strand DNA synthesis and primer removal. J Biol Chem (1999) 1.27
Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob Agents Chemother (1999) 1.26
Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase. Protein Expr Purif (1996) 1.25
Inducible expression of IkappaBalpha repressor mutants interferes with NF-kappaB activity and HIV-1 replication in Jurkat T cells. J Biol Chem (1998) 1.23
Clindamycin with primaquine for Pneumocystis carinii pneumonia. Lancet (1989) 1.22
Infection of human monocytes/macrophages by HIV-1: effect on secretion of IL-1 activity. Immunology (1988) 1.22
Live imaging of Toll-like receptor 2 response in cerebral ischaemia reveals a role of olfactory bulb microglia as modulators of inflammation. Brain (2009) 1.21
Variant effects of non-native kissing-loop hairpin palindromes on HIV replication and HIV RNA dimerization: role of stem-loop B in HIV replication and HIV RNA dimerization. Biochemistry (1999) 1.21
Primer tRNA3Lys on the viral genome exists in unextended and two-base extended forms within mature human immunodeficiency virus type 1. J Virol (1997) 1.20
Effect of mutations in the nucleocapsid protein (NCp7) upon Pr160(gag-pol) and tRNA(Lys) incorporation into human immunodeficiency virus type 1. J Virol (1997) 1.19
Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris. Virology (1992) 1.18
Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1. J Virol (1996) 1.18
The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase. J Biol Chem (1996) 1.16
Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother (1996) 1.16
Mechanisms of virus-induced immune suppression. Can Med Assoc J (1985) 1.14
Deletion mutagenesis within the dimerization initiation site of human immunodeficiency virus type 1 results in delayed processing of the p2 peptide from precursor proteins. J Virol (1999) 1.14
Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells. J Exp Med (1990) 1.13
Alcoholism and rapid progression to AIDS after seroconversion. Clin Infect Dis (1994) 1.12
In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Antiviral Res (1996) 1.12
Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. Antimicrob Agents Chemother (1999) 1.11
Orthostatic intolerance in the chronic fatigue syndrome. J Auton Nerv Syst (1999) 1.11
Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins. J Mol Biol (1998) 1.10
Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res (1997) 1.10
Cell-specific differences in activation of NF-kappa B regulatory elements of human immunodeficiency virus and beta interferon promoters by tumor necrosis factor. J Virol (1990) 1.10
Enhanced impairment of chain elongation by inhibitors of HIV reverse transcriptase in cell-free reactions yielding longer DNA products. Nucleic Acids Res (1998) 1.10
Coordinate enhancement of cytokine gene expression in human immunodeficiency virus type 1-infected promonocytic cells. J Virol (1990) 1.09
The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 1.09
Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol (2004) 1.09
Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother (1994) 1.09
Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs. Antimicrob Agents Chemother (1991) 1.09
Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1. J Virol (1999) 1.08
Cellular immunity against Rous sarcomas of chickens. Preferential reactivity against autochthonous target cells as determined by lymphocyte adherence and cytotoxicity tests in vitro. Proc Natl Acad Sci U S A (1974) 1.08
Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. J Clin Microbiol (1994) 1.08
Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity. Hum Mol Genet (1993) 1.08
Monoclonal antibody-mediated inhibition of HIV-1 reverse transcriptase polymerase activity. Interaction with a possible deoxynucleoside triphosphate binding domain. J Biol Chem (1993) 1.07
Detection of unintegrated human immunodeficiency virus type 1 DNA in persistently infected CD8+ cells. J Gen Virol (1993) 1.07
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS (2001) 1.07
Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases. J Leukoc Biol (1989) 1.07
Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2003) 1.06
Why are there so many myths about AIDS? CMAJ (1993) 1.06
Roles of Pr55(gag) and NCp7 in tRNA(3)(Lys) genomic placement and the initiation step of reverse transcription in human immunodeficiency virus type 1. J Virol (2000) 1.06
Cell surface down-modulation of CD4 after infection by HIV-1. FASEB J (1994) 1.06
Viral inhibition of lymphocyte mitogenesis: interference with the synthesis of functionally active T cell growth factor (TCGF) activity and reversal of inhibition by the addition of same. J Immunol (1983) 1.05
Human immunodeficiency virus, genital ulcers and the male foreskin: synergism in HIV-1 transmission. Scand J Infect Dis Suppl (1990) 1.04
Stavudine resistance: an update on susceptibility following prolonged therapy. Antivir Ther (1999) 1.04
Association of p56lck with the cytoplasmic domain of CD4 modulates HIV-1 expression. EMBO J (1994) 1.04
Role of distal zinc finger of nucleocapsid protein in genomic RNA dimerization of human immunodeficiency virus type 1; no role for the palindrome crowning the R-U5 hairpin. Virology (2001) 1.04
Leader sequences downstream of the primer binding site are important for efficient replication of simian immunodeficiency virus. J Virol (2000) 1.04